ALSUntangled 55: vitamin E (α-tocopherol)

References

• Fulgoni V, Keast D, Bailey R, Dwyer J. Foods, fortificants, and supplements: where do Americans get their nutrients? J Nutr. 2011;141:1847–54.
   PubMed Web of Science ®Google Scholar
• National Institute of Health [online]; 2020. Updated February 28, 2020. Accessed March 15, 2020. Available at: https://ods.od.nih.gov/factsheets/VitaminE-HealthProfessional/
   Google Scholar
• Azzi A. Many tocopherols, one vitamin E. Mol Aspects Med. 2018;61:92–103.
   PubMed Web of Science ®Google Scholar
• Satya-Murti S, Howard L, Krohel G, Wolf B. The spectrum of neurologic disorder from vitamin E deficiency. Neurology. 1986;36:917–21.
   PubMed Web of Science ®Google Scholar
• Iwasaki Y, Ikeda K, Kinoshita M. Vitamin A and E levels are normal in amyotrophic lateral sclerosis. J Neurol Sci. 1995;132:193–4.
   PubMed Web of Science ®Google Scholar
• Oteiza P, Uchitel O, Carrasquedo F, Dubrovski A, Roma J, Fraga C. Evaluation of antioxidants, protein, and lipid oxidation products in blood from sporadic amiotrophic lateral sclerosis patients. Neurochem Res. 1997;22:535–9.
   PubMed Web of Science ®Google Scholar
• de Bustos F, Jiménez-Jiménez FJ, Molina JA, Esteban J, Guerrero-Sola A, Zurdo M, et al. Cerebrospinal fluid levels of alpha-tocopherol in amyotrophic lateral sclerosis. J Neural Transm. 1998;105:703–8.
   PubMed Web of Science ®Google Scholar
• Traber M, Atkinson J. Vitamin E, antioxidant and nothing more. Free Radic Biol Med. 2007;43:4–15.
   PubMed Web of Science ®Google Scholar
• Zingg J. Vitamin E: a role in signal transduction. Annu Rev Nutr. 2015;35:135–73.
   PubMed Web of Science ®Google Scholar
• ALS Worldwide [online]; 2020. Accessed March 15, 2020. Available at: https://alsworldwide.org/care-and-support/article/supplements-and-vitamins
   Google Scholar
• Vardeny O, Bromberg MB. The use of herbal supplements and alternative therapies by patients with amyotrophic lateral sclerosis (ALS). J Herb Pharmacother. 2005;5:23–31.
   PubMedGoogle Scholar
• Vatassery G, Fahn S, Kuskowski M. Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Parkinson Study Group. Neurology. 1998;50:1900–2.
   PubMed Web of Science ®Google Scholar
• Thonhoff J, Simpson E, Appel S. Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis. Curr Opin Neurol. 2018;3:635–9.
   Google Scholar
• Sako W, Ito H, Yoshida M, Koizumi H, Kamada M, Fujita K, et al. Nuclear factor-κB expression in patients with sporadic amyotrophic lateral sclerosis and hereditary amyotrophic lateral sclerosis with optineurin mutations. Clin Neuropathol. 2012;31:418–23.
   PubMed Web of Science ®Google Scholar
• Swarup V, Phaneuf D, Dupré N, Petri S, Strong M, Kriz J, et al. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor kappa B-mediated pathogenic pathways. J Exp Med. 2011;208:2429–47.
   PubMed Web of Science ®Google Scholar
• Frakes AE, Ferraiuolo L, Haidet-Phillips AM, Schmelzer L, Braun L, Miranda CJ, et al. Microglia induce motor neuron death via the classical NF-kB pathway in amyotrophic lateral sclerosis. Neuron. 2014;81:1009–23.
   PubMed Web of Science ®Google Scholar
• Patel P, Julien JP, Kriz J. Early-stage treatment with withaferin A reduces levels of misfolded superoxide dismutase 1 and extends lifespan in a mouse model of amyotrophic lateral sclerosis. Neurotherapeutics. 2015;12:217–33.
   PubMed Web of Science ®Google Scholar
• Lyon M, Wosiski-Kuhn M, Gillespie R, Caress J, Milligan C. Inflammation, immunity and amyotrophic lateral sclerosis: I. Etiology and pathology. Muscle Nerve. 2019;59:10–22.
   PubMed Web of Science ®Google Scholar
• Wosiski-Kuhn M, Lyon M, Caress J, Milligan C. Inflammation, immunity, and amyotrophic lateral sclerosis: II. Immune-modulating therapies. Muscle Nerve. 2019;59:23–33.
   PubMed Web of Science ®Google Scholar
• Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hernández M, et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:5–14.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Packer L. Inhibition of NF-KB activation by vitamin E derivatives. Biochem Biophys Res Commun. 1993;193:277–83.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Packer L. Inhibition of NF-kappa B DNA binding activity by alpha-tocopheryl succinate. Biochem Mol Biol Int. 1993;31:693–700.
   PubMedGoogle Scholar
• Crayle J, Bedlack R. ALSUntangled 47: RT001. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:294–7.
   PubMed Web of Science ®Google Scholar
• Kaal ECA, Veldman H, Sodaar P, Joosten EAJ, Dop Bär PR. Oxidant treatment causes a dose-dependent phenotype of apoptosis in cultured motoneurons. J Neurosci Res. 1998;54:778–86.
   PubMed Web of Science ®Google Scholar
• Zakharova I, Sokolova T, Vlasova Y, Bayunova L, Rychkova M, Avrova N. alpha-tocopherol at nanomolar concentration protects cortical neurons against oxidative stress. Int J Mol Sci. 2017;18:216.
   Web of Science ®Google Scholar
• Mazlan M, Mian T, Top G, Ngah W. Comparative effects of a-tocopherol and g-tocotrienol against hydrogen peroxide induced apoptosis on primary-cultured astrocytes. J Neurol Sci. 2006;243:5–12.
   PubMed Web of Science ®Google Scholar
• Pedersen W, Cashman N, Mattson M. The lipid peroxidation product 4-hydroxynonenal impairs glutamate and glucose transport and choline acetyltransferase activity in NSC-19 motor neuron cells. Exp Neurol. 1999;155:1–10.
   PubMed Web of Science ®Google Scholar
• Jang S, Lim J, Im B, Baek W, Song D. Comparison of riluzole with N-acetylcysteine and vitamin E against H2O2- and glutamate-induced cytotoxicity in a motor neuron cell line. Curr Top Nutraceut Res. 2007;5:99–106.
   Web of Science ®Google Scholar
• Choi J, Conrad CC, Dai R, Malakowsky CA, Talent JM, Carroll CA, et al. Vitamin E prevents oxidation of antiapoptotic proteins in neuronal cells. Proteomics. 2003;3:73–7.
   PubMed Web of Science ®Google Scholar
• Vatassery G, Brin M, Fahn S, Kayden H, Traber M. Effect of high doses of dietary vitamin E on the concentrations of vitamin E in several brain regions, plasma, liver, and adipose tissue of rats. J Neurochem. 1988;51:621–3.
   PubMed Web of Science ®Google Scholar
• Sharma N, Nehru B. Beneficial effect of vitamin E in rotenone induced model of PD: behavioural, neurochemical and biochemical study. Exp Neurobiol. 2013;22:214–23.
   PubMedGoogle Scholar
• Patrignani P, Panara MR, Tacconelli S, Seta F, Bucciarelli T, Ciabattoni G, et al. Effects of vitamin E supplementation on F2-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. Circulation. 2000;102:539–45.
   PubMed Web of Science ®Google Scholar
• Meagher E, Barry O, Lawson J, Rokach J, FitzGerald G. Effects of vitamin E on lipid peroxidation in healthy persons. JAMA. 2001;285:1178–82.
   PubMed Web of Science ®Google Scholar
• Huang H, Appel L, Croft K, Miller E, Mori T, Puddey I. Effects of vitamin C and vitamin E on in vivo lipid peroxidation: results of a randomized controlled trial. Am J Clin Nutr. 2002;76:549–55.
   PubMed Web of Science ®Google Scholar
• Keith ME, Jeejeebhoy KN, Langer A, Kurian R, Barr A, O'Kelly B, et al. A controlled clinical trial of vitamin E supplementation in patients with congestive heart failure. Am J Clin Nutr. 2001;73:219–24.
   PubMed Web of Science ®Google Scholar
• Robertsii L, Oates J, Linton M, Fazio S, Meador B, Gross M, et al. The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free Radic Biol Med. 2007;43:1388–93.
   PubMed Web of Science ®Google Scholar
• Devaraj S, Tang R, Adams-Huet B, Harris A, Seenivasan T, de Lemos JA, et al. Effect of high-dose α-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease. Am J Clin Nutr. 2007;86:1392–8.
   PubMed Web of Science ®Google Scholar
• Kaikkonen J, Porkkala-Sarataho E, Morrow JD, Roberts LJ, Nyyssönen K, Salonen R, et al. Supplementation with vitamin E but not with vitamin C lowers lipid peroxidation in vivo in mildly hypercholesterolemic men. Free Radic Res. 2001;35:967–78.
   PubMed Web of Science ®Google Scholar
• Guertin KA, Grant RK, Arnold KB, Burwell L, Hartline J, Goodman PJ, et al. Effect of long-term vitamin E and selenium supplementation on urine F2-isoprostanes, a biomarker of oxidative stress. Free Radic Biol Med. 2016;95:349–56.
   PubMed Web of Science ®Google Scholar
• The ALSUntangled Group. ALSUntangled 38: l-serine. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:148–51.
   PubMed Web of Science ®Google Scholar
• Okle O, Stemmer K, Deschl U, Dietrich D. l-BMAA induced ER stress and enhanced caspase 12 cleavage in human neuroblastoma SH-SY5Y cells at low nonexcitotoxic concentrations. Toxicol Sci. 2013;131:217–24.
   PubMed Web of Science ®Google Scholar
• Terro F, Lesort M, Viader F, Ludolph A, Hugon J. Antioxidant drugs block in vitro the neurotoxicity of CSF from patients with amyotrophic lateral sclerosis. NeuroReport. 1996;7:1970–2.
   PubMed Web of Science ®Google Scholar
• Ghadge GD, Lee JP, Bindokas VP, Jordan J, Ma L, Miller RJ, et al. Mutant superoxide dismutase-1-linked familial amyotrophic lateral sclerosis: molecular mechanisms of neuronal death and protection. J Neurosci. 1997;17:8756–66.
   PubMed Web of Science ®Google Scholar
• Kruman I, Pedersen W, Springer J, Mattson M. ALS-linked Cu/Zn-SOD mutation increases vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis. Exp Neurol. 1999;160:28–39.
   PubMed Web of Science ®Google Scholar
• Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, et al. Benefit of vitamin E, riluzole, gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol. 1996;39:147–57.
   PubMed Web of Science ®Google Scholar
• Kong Q, Carothers S, Chang Y, Glenn Lin C-L. The importance of preclinical trial timing – a potential reason for the disconnect between mouse studies and human clinical trials in ALS. CNS Neurosci Ther. 2012;18:791–3.
   PubMed Web of Science ®Google Scholar
• DeJong R. Vitamin E and alpha tocopherol therapy of neuromuscular and muscular disorders. Arch Neurol Psychiatry. 1941;46:1068–75.
   Google Scholar
• Wechsler I. Treatment of amyotrophic lateral sclerosis with vitamin E. Am J Med Sci. 1940;200:765–78.
   Google Scholar
• Wechsler I. Recovery in ALS, treated with tocopherols: preliminary report. JAMA. 1940;114:948–50.
   Google Scholar
• New York Academy of Medicine, Section of Neurology and Psychiatry, and New York Neurological Society. Society Transactions Nov 12, 1940: amyotrophic lateral sclerosis treated with synthetic vitamin E. Arch Neurol Psychiatry. 1941;45:873–86.
   Google Scholar
• Bicknell F. Vitamin E in the treatment of muscular dystrophies and nervous diseases. Lancet. 1940;235:10–3.
   Google Scholar
• Spies T. The vitamin B deficiencies. Trans Stud Coll Phys Philadelphia. 1941;8:12–26.
   Google Scholar
• Rosenberger A. Observations on the treatment of amyotrophic lateral sclerosis with vitamin E. Med Rec. 1941;154:97–100.
   Google Scholar
• Weber J, Clinco A. Report of a case of amyotrophic lateral sclerosis treated with vitamin E. Med Times. 1942;70:247–9.
   Google Scholar
• Sheldon C, Butt H, Woltman H. Vitamin E therapy in certain neurologic disorders. Proc Staff Meet Mayo Clin. 1940;15:577–80.
   Google Scholar
• Eaton L, Woltman W, Butt H. Vitamin E and B6 in the treatment of neuromuscular diseases. Proc Staff Meet Mayo Clin. 1941;16:523–528.
   Google Scholar
• Ferrebee J, Klingman W, Frantz A. Vitamin E and vitamin B6: clinical experience in the treatment of muscular dystrophy and amyotrophic lateral sclerosis. JAMA. 1941;116:1895–6.
   Google Scholar
• Denker P, Scheinman L. Treatment of amyotrophic lateral sclerosis with vitamin E. JAMA. 1941;116:1893–5.
   Google Scholar
• Merwarth H. Synthetic vitamin E in the treatment of amyotrophic lateral sclerosis and related disorders. Dis Nerv Syst. 1941;2:325–9.
   Google Scholar
• Davison C. Effect of vitamin E therapy on the central nervous system in amyotrophic lateral sclerosis. Am J Pathol. 1943;19:883–99.
   PubMedGoogle Scholar
• Davison C. Effect of vitamin E therapy on the central nervous system in amyotrophic lateral sclerosis. Bull N Y Acad Med. 1943;19:386–416.
   PubMedGoogle Scholar
• Doyle A, Merritt H. Vitamin therapy of the diseases of the neuromuscular apparatus. Arch Neurol Psychiatry. 1941;45:672–9.
   Google Scholar
• Schwarz G, Gammon G, Masland R. Use of d-l alpha tocopherol acetate in various neuromuscular disturbances. J Nerv Ment Dis. 1942;96:286–95.
   Google Scholar
• Zech V, Telford I. Negative therapeutic effect of massive doses of vitamin E on amyotrophic lateral sclerosis. Arch Neurol Psychiatry. 1943;50:190–2.
   Google Scholar
• Lubin A. Use of alpha tocopherol in the treatment of neuromuscular disorders. Arch Intern Med. 1942;69:836–55.
   Google Scholar
• Harvey R, Hume P. Vitamin E and nervous diseases. California West Med. 1941;55:293–5.
   PubMedGoogle Scholar
• Fitzgerald G, McArdle B. Vitamins E and B6 in the treatment of muscular dystrophy and motor neurone disease. Brain. 1941;64:19–42.
   Google Scholar
• Worster-Drought C, Shafar J. Motor neurone degeneration treated with vitamin E. Lancet. 1941;238:209–12.
   Google Scholar
• Rabinovitch R, Gibson W, McEachern D. Neuromuscular disorders amenable to wheat germ oil therapy. J Neurol Neurosurg Psychiat. 1951;14:95–100.
   PubMed Web of Science ®Google Scholar
• Quick D, Greer M. Pancreatic dysfunction in patients with amyotrophic lateral sclerosis. Neurology. 1967;17:112–6.
   PubMed Web of Science ®Google Scholar
• Dorman J, Engel W, Fried D. Therapeutic trial in amyotrophic lateral sclerosis. JAMA. 1969;209:257–8.
   PubMed Web of Science ®Google Scholar
• Norris F, Denys E. Nutritional supplements in amyotrophic lateral sclerosis. In: Cosi V, ed. AEMB: amyotrophic lateral sclerosis. Vol. 209. Boston: Springer; 1987.
   Google Scholar
• PatientsLikeMe [online]; 2020. Accessed March 19, 2020. Available at: https://www.patientslikeme.com/treatment/vitamin-e
   Google Scholar
• Harrison D, Mehta P, van Es MA, Stommel E, Drory VE, Nefussy B, van den Berg LH. “ALS reversals”: demographics, disease characteristics, treatments, and co-morbidities. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:495–9.
   PubMed Web of Science ®Google Scholar
• Crayle J, Bedlack R. unpublished data.
   Google Scholar
• Desnuelle C, Dib M, Garrel C, Favier A, and the ALS Riluzole-Tocopherol Study Group. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS Other Motor Neuron Disord. 2001;2:9–18.
   PubMed Web of Science ®Google Scholar
• Kwiecinski H, Janik P, Jamrozik Z, Opuchlik A. The effect of selegiline and vitamin E in the treatment of ALS: an open randomized clinical trial. Neurol Neurochir Pol. 2001;35:101–6.
   PubMedGoogle Scholar
• Orrell R, Lane R, Ross M. A systematic review of antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease. Amyotroph Lateral Scler. 2008;9:195–211.
   PubMed Web of Science ®Google Scholar
• Graf M, Ecker D, Horowski R, Kramer B, Riederer P, Gerlach M, et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm. 2005;112:649–60.
   PubMed Web of Science ®Google Scholar
• Longnecker MP, Kamel F, Umbach DM, Munsat TL, Shefner JM, Lansdell LW, et al. Dietary intake of calcium, magnesium and antioxidants in relation to risk of amyotrophic lateral sclerosis. Neuroepidemiology. 2000;19:210–6.
   PubMed Web of Science ®Google Scholar
• Nelson LM, Matkin C, Longstreth WT, McGuire V. Population-based case-control study of amyotrophic lateral sclerosis in Western Washington State. II. Diet. Am J Epidemiol. 2000;151:164–73.
   PubMed Web of Science ®Google Scholar
• Okamoto K, Kihira T, Kobashi G, Washio M, Sasaki S, Yokoyama T, et al. Fruit and vegetable intake and risk of amyotrophic lateral sclerosis in Japan. Neuroepidemiology. 2009;32:251–6.
   PubMed Web of Science ®Google Scholar
• Veldink JH, Kalmijn S, Groeneveld G-J, Wunderink W, Koster A, de Vries JHM, et al. Intake of polyunsaturated fatty acids and vitamin E reduces the risk of developing amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2006;78:367–71.
   PubMed Web of Science ®Google Scholar
• Ascherio A, Weisskopf MG, O'Reilly EJ, Jacobs EJ, McCullough ML, Calle EE, et al. Vitamin E Intake and risk of amyotrophic lateral sclerosis. Ann Neurol. 2005;57:104–10.
   PubMed Web of Science ®Google Scholar
• Wang H, O'Reilly EJ, Weisskopf MG, Logroscino G, McCullough ML, Schatzkin A, et al. Vitamin E intake and risk of amyotrophic lateral sclerosis: a pooled analysis of data from 5 prospective cohort studies. Am J Epidemiol. 2011;173:595–602.
   PubMed Web of Science ®Google Scholar
• Freedman D, Kuncl R, Weinstein S, Malila N, Virtamo J, Albanes D. Vitamin E serum levels and controlled supplementation and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:246–51.
   PubMed Web of Science ®Google Scholar
• Hathcock JN, Azzi A, Blumberg J, Bray T, Dickinson A, Frei B, et al. Vitamins E and C are safe across a broad range of intakes. Am J Clin Nutr. 2005;81:736–45.
   PubMed Web of Science ®Google Scholar
• Schurks M, Glynn R, Rist P, Tzourio C, Kurth T. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ. 2010;341:c5702.
   PubMed Web of Science ®Google Scholar
• Stanger MJ, Thompson LA, Young AJ, Lieberman HR. Anticoagulant activity of select dietary supplements. Nutr Rev. 2012;70:107–17.
   PubMed Web of Science ®Google Scholar
• Pastori D, Carnevale R, Cangemi R, Saliola M, Nocella C. Vitamin E serum levels and bleeding risk in patients receiving oral anticoagulant therapy: a retrospective cohort study. J Am Heart Assoc. 2013;2:e000364.
   PubMed Web of Science ®Google Scholar
• Klein EA, Thompson IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: updated results of the selenium and vitamin E cancer prevention trial. JAMA. 2011;306:1549–56.
   PubMed Web of Science ®Google Scholar
• The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994;330:1029–35.
   PubMed Web of Science ®Google Scholar
• Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the physicians health study II randomized controlled trial. JAMA. 2009;301:52–62.
   PubMed Web of Science ®Google Scholar
• Target [online]. Accessed March 20, 2020. Available at: https://www.target.com/p/vitamin-e-1000iu-softgels-200ct-up-up-8482/-/A-75001600
   Google Scholar